Castle Biosciences, Inc. (CSTL)

Castle Biosciences beat expectations in the second fiscal quarter of 2026, with revenue and EPS both topping consensus when results were reported July 30, 2026. Revenue rose 20.1% to about $103.5 million, and in the consensus comparison it topped expectations at $103.5 million versus the $86.2 million estimate, +20.1%, up from about $86.2 million a year ago. EPS of -$0.07 topped the -$0.41 estimate by $0.34, swinging from $0.15 a year ago. Profitability stayed high at the gross line with gross margin at roughly 77%, while operating margin was about -3% as the company posted an operating loss of roughly $3.1 million; net income was a loss of about $2.1 million versus about $4.5 million a year ago. The quarter generated operating cash flow of around $15.2 million. For the next period, consensus calls for EPS of -$0.38 on revenue of $92.1 million.